CN112261938A - (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗耳鸣、急性感音神经性听力损失、梅尼埃病、图雷特氏综合征、注意缺陷多动障碍和成瘾中的用途 - Google Patents

(1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗耳鸣、急性感音神经性听力损失、梅尼埃病、图雷特氏综合征、注意缺陷多动障碍和成瘾中的用途 Download PDF

Info

Publication number
CN112261938A
CN112261938A CN201980023215.6A CN201980023215A CN112261938A CN 112261938 A CN112261938 A CN 112261938A CN 201980023215 A CN201980023215 A CN 201980023215A CN 112261938 A CN112261938 A CN 112261938A
Authority
CN
China
Prior art keywords
amino
difluoromethylene
carboxylic acid
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980023215.6A
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of CN112261938A publication Critical patent/CN112261938A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980023215.6A 2018-02-08 2019-02-08 (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗耳鸣、急性感音神经性听力损失、梅尼埃病、图雷特氏综合征、注意缺陷多动障碍和成瘾中的用途 Pending CN112261938A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862628020P 2018-02-08 2018-02-08
US62/628,020 2018-02-08
US201862628541P 2018-02-09 2018-02-09
US62/628,541 2018-02-09
PCT/US2019/017201 WO2019157273A1 (en) 2018-02-08 2019-02-08 Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction

Publications (1)

Publication Number Publication Date
CN112261938A true CN112261938A (zh) 2021-01-22

Family

ID=67475310

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980023215.6A Pending CN112261938A (zh) 2018-02-08 2019-02-08 (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗耳鸣、急性感音神经性听力损失、梅尼埃病、图雷特氏综合征、注意缺陷多动障碍和成瘾中的用途

Country Status (10)

Country Link
US (1) US10653652B2 (cg-RX-API-DMAC7.html)
EP (1) EP3735237A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021512920A (cg-RX-API-DMAC7.html)
KR (3) KR20240154700A (cg-RX-API-DMAC7.html)
CN (1) CN112261938A (cg-RX-API-DMAC7.html)
AU (1) AU2019216742B2 (cg-RX-API-DMAC7.html)
CA (1) CA3090258A1 (cg-RX-API-DMAC7.html)
IL (1) IL276287B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020008359A (cg-RX-API-DMAC7.html)
WO (1) WO2019157273A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112218628A (zh) * 2018-03-29 2021-01-12 奥维德医疗公司 (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗眼紊乱中的用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX389001B (es) 2015-10-23 2025-03-20 Navitor Pharm Inc Moduladores de interacción de sestrina-gator2 y sus usos.
ES3040534T3 (en) 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
US11771671B2 (en) 2018-02-08 2023-10-03 Ovid Therapeutics Inc. Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
WO2020086816A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
AU2020376950B2 (en) 2019-11-01 2026-06-11 Supernus Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
US12678586B1 (en) 2023-06-12 2026-07-14 John Brundage Noise injury relief system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150044200A1 (en) * 2011-12-12 2015-02-12 Otolanum Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794413B1 (en) * 2002-07-19 2004-09-21 Northwestern University Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase
US6656172B1 (en) * 2002-09-27 2003-12-02 Medtronic, Inc. Method for treating severe tinnitus
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
CA2790820A1 (en) 2010-02-25 2011-09-01 Northwestern University Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor
US20130230586A1 (en) * 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
WO2013006857A1 (en) 2011-07-07 2013-01-10 The Children's Hospital Of Philadelphia Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
WO2013112363A1 (en) * 2012-01-27 2013-08-01 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
CN108137484B (zh) * 2015-10-09 2021-02-12 西北大学 作为用于治疗癫痫、成瘾和肝细胞癌的gaba氨基转移酶灭活剂的化合物
KR20240110989A (ko) 2017-02-08 2024-07-16 오비드 테라퓨틱스 인크. 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150044200A1 (en) * 2011-12-12 2015-02-12 Otolanum Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOSE I. JUNCOSA等: "Design and Mechanism of (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid, a HighlyPotent GABA Aminotransferase Inactivator for the Treatment of Addiction", 《JOURNAL OF THE AMERICAN CHEMICAL SOCIETY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112218628A (zh) * 2018-03-29 2021-01-12 奥维德医疗公司 (1s,3s)-3-氨基-4-(二氟亚甲基)环戊烷-1-甲酸和(s)-3-氨基-4-(二氟亚甲基)环戊-1-烯-1-甲酸在治疗眼紊乱中的用途

Also Published As

Publication number Publication date
MX2020008359A (es) 2020-11-24
KR20240154700A (ko) 2024-10-25
JP2021512920A (ja) 2021-05-20
KR20250167147A (ko) 2025-11-28
WO2019157273A1 (en) 2019-08-15
CA3090258A1 (en) 2019-08-15
US20190240174A1 (en) 2019-08-08
KR20210007948A (ko) 2021-01-20
EP3735237A4 (en) 2021-03-17
EP3735237A1 (en) 2020-11-11
AU2019216742A1 (en) 2020-08-13
IL276287B1 (en) 2026-07-01
IL276287A (en) 2020-09-30
AU2019216742B2 (en) 2024-05-09
US10653652B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
US10653652B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction
AU2009201019B2 (en) Dosage form containing oxycodone and naloxone
AU2002311784B2 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
JP2024178317A (ja) 耳鳴りの処置におけるガボキサドールの使用
US20060252761A1 (en) Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
JP7387179B2 (ja) 発達障害の処置における(s)-3-アミノ-4-(ジフルオロメチレニル)シクロペンタ-1-エン-1-カルボン酸および関連化合物、(1s,3s)-3-アミノ-4-(ジフルオロメチリデン)シクロペンタン-1-カルボン酸ならびにビガバトリンの使用
AU2002311784A1 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US11771671B2 (en) Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
CN106459066B (zh) 治疗睡眠过度的方法
JP2022540917A (ja) 治療的処置のためのガボキサドール含有医薬製剤
KR20210038843A (ko) 주의력 결핍 과잉 행동 장애를 치료하는 방법
WO2005016319A2 (en) Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
HK40015478A (en) Use of gaboxadol in the treatment of tinnitus
CA2524090A1 (en) Use of tripolidine in providing refreshedness on waking
HK1150754A (en) Dosage form containing oxycodone and naloxone

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination